Kowa Pharmaceuticals America

Newsroom

Abstract newsroom and communications imagery for Kowa Pharmaceuticals America, Inc.

Press releases

  • MAY 12, 2026

    Kowa announces topline results from the NCX 470 Phase 3 glaucoma program

  • APRIL 3, 2026

    Denali and Mont Blanc Phase 3 studies advance Kowa's ophthalmology pipeline

  • FEBRUARY 27, 2026

    Kowa to present at the 2026 American Glaucoma Society Annual Meeting

Publications

  • MAY 10, 2026

    Placeholder: NCX 470 Phase 3 Efficacy and Safety — Poster Presentation

  • MARCH 18, 2026

    Placeholder: Mechanisms of Optic Nerve Protection in Glaucoma — Review Article

  • NOVEMBER 4, 2025

    Placeholder: Comparative Efficacy of Novel IOP-Lowering Agents in Open-Angle Glaucoma

Explore Our Products and Pipeline